Long-term outcomes following Sacubitril/Valsartan therapy for chronic HFrEF. Italian Real-World Multicenter Study
S/V initiation was associated with sustained improvements in NT-proBNP, quality of life and cardiac remodeling. S/V discontinuation or dose reduction identified patients at higher MACE risk.
Authors
- E Mariano
- E Salvioni
- Gianluigi Savarese (ORCID: https://orcid.org/0000-0001-7732-0887)
- Giuseppe Dattilo (ORCID: https://orcid.org/0000-0002-6681-0183)
- Egidio Imbalzano (ORCID: https://orcid.org/0000-0003-2656-5467)
- P. Agostoni
- Gianpaolo Palmieri
- Francesco Paolo Niglio
- Roberto Licordari (ORCID: https://orcid.org/0000-0003-3185-9240)
- Erberto Carluccio (ORCID: https://orcid.org/0000-0002-9296-4397)
- Francesco Loria (ORCID: https://orcid.org/0000-0002-6615-3662)
- Francesca Barillà
- S Pavoncelli
- Antonio Cannata
- Alberto Aimo
- Massimo Mapelli
- Michele Emdin
- Michele Ciccarelli
- Michele Correale
- Gianluca Di Bella
- Frank L Dini
- Alberto Palazzuoli
Institutions
- University of Foggia (IT)
- University of Messina (IT)
- University of Salerno (IT)
- Karolinska University Hospital (SE)
- Scuola Superiore Sant'Anna (IT)
- University of Milan (IT)
- Karolinska Institutet (SE)
- British Heart Foundation (GB)
- Centro Cardiologico Monzino (IT)
- Ospedali Riuniti di Foggia (IT)
- Ospedale Santa Maria alle Scotte (IT)
- King's College Hospital NHS Foundation Trust (GB)
- IRCCS Istituto Auxologico Italiano (IT)
- Policlinico Tor Vergata (IT)
- Fondazione Toscana Gabriele Monasterio (IT)
- Misericordia University (US)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1093/eschf/xvag082
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00